Drug Type Small molecule drug |
Synonyms [18F]meta-fluorobenzylguanidine, Florbenguane (18F), Florbenguane F18(USAN) + [1] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC8H10FN3 |
InChIKeyHNPHEZIYSZIWHH-RVRFMXCPSA-N |
CAS Registry156021-12-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroblastoma | Phase 3 | United States | 18 Nov 2021 | |
Lewy Body Disease | Phase 2 | - | 30 Oct 2025 | |
Parkinson Disease | Phase 2 | - | 30 Oct 2025 | |
Heart Failure | Phase 2 | United States | 30 Sep 2025 | |
Ischemic cardiomyopathy | Phase 2 | United States | 30 Sep 2025 | |
Mucolipidoses | Phase 2 | United States | 30 Sep 2025 | |
Neural Crest Tumor | Phase 2 | United States | 01 Jan 2025 | |
Pheochromocytoma | Phase 2 | United States | 01 Jan 2025 | |
Arrhythmias, Cardiac | Phase 2 | United States | 05 Nov 2021 | |
Coronary Artery Disease | Phase 2 | United States | 05 Nov 2021 |
Not Applicable | - | (MFBG PET imaging) | fvrkifvpvd(psohmgqchf) = No severe adverse events were noted in patients after MFBG injection jzauyuskeb (ohzdmhxnrd ) | - | 28 Aug 2023 | ||
(MIBG imaging) |